• Topadur Pharma AG and Oshen Holdings SA agree partnership to develop a treatment for alopecia. The agreement includes equity and development costs totaling CHF 15 million.
  • Microcaps AG secures CHF 9.3 million in series a financing round to expand production capacity.
  • CUTISS announces first closing of CHF 25 million in Series C funding round.
  • Memo Therapeutics increases series C financing to CHF 45 million.
  • hemotune raises CHF 14 million Series B2 funding for clinical trials with the HemoSystem.
  • EraCal Therapeutics enters into a collaboration and license agreement with Novo Nordisk. EraCal is eligible to receive upfront, development, and commercial milestones of up to 235 million EURO and further royalties on sales of a marketed product.
  • Biognosys Expands US Footprint with New Proteomics CRO Facility in Massachusetts.
  • DISCO Pharmaceuticals launches with EUR 20 million in seed financing.
  • The City of Zurich joins the Bio-Technopark Schlieren-Zurich as a member.
  • GlycoEra AG announces Bristol Myers Squibb as new investor.


  • Proteomedix acquired by Blue Water Biotech to form Onconetix Inc., a commercial stage men’s health pharma and diagnostics company.
  • Ferring and PharmaBiome enter into a new microbiome R&D collaboration and exclusive licensing agreement.
  • Memo Therapeutics AG raises CHF 25 million series C financing to complete phase 2 clinical development of AntiBKV for BKV infection in renal transplant patients.
  • Rejuveron raises USD 75 million in dual tranche Series B and convertible loan financing to support healthy aging and accelerate presence in the Middle East.
  • LimmaTech Biologics raises $37 million series A to advance its pipeline of vaccines against multidrug-resistant bacterial infections.
  • Luciole Medical AG acquires Spiegelberg GmbH & Co. KG to create a leading global brain monitoring developer and provider.
  • Siegfried acquires 95% of DiNAMIQS, a subsidiary of DiNAQOR, which retains 5% stake. Siegfried intends to establish DiNAMIQS as a best-in-class biotech CDMO for medical cell and gene therapies by building a state-of-the-art GMP-compliant production facility in the Bio-Technopark.
  • ETH Zurich strengthens medical research with new site at Bio-Technopark.
  • CUTISS announces positive results from phase 2 clinical trial with denovoSkin™ in adolescent and adult burn patients and from phase 1 study in children.
  • InSphero receives an eight-digit amount from ZEISS Ventures in a financing round to commercialize 3D microtissue technology and to build a biobank.
  • Biognosys and Bruker form partnership, in which Bruker has made a majority-ownership investment in Biognosys.


  • ETH Zurich becomes a member of the Bio-Technopark and is represented locally with ETH Entrepreneurship and the technology platform NEXUS.
  • ImmunOs Therapeutics raises CHF 71 million in Series B Financing, led by top investor syndicate to advance cancer immunotherapy agent into human trials.
  • CDR-Life raises US$76 million in a series A funding. Proceeds support advancement of the M-gager® platform technology and lead product candidate CDR404.
  • Memo Therapeutics closes series B financing at CHF 37 million following oversubscribed CHF 23 million extension. Proceeds will be used to advance antibody against BK virus through Phase 2 clinical development.
  • Neurimmune enters into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, to develop NI006 for the treatment of cardiomyopathy. Neurimmune receives an upfront payment of US$30 million with the potential for additional contingent milestone payments of up to US$730 million.
  • Endogena completes series A with total funding of $29 million to progress treatments for degenerative diseases of the eye.


  • Molecular Partners collaborates with Novartis to develop DARPin-conjugated radioligand therapeutic candidates for oncology. Novartis will pay US$ 20 million upfront to Molecular Partners, total potential development, regulatory and commercialization milestone payments of up to US$ 560 million, and up to low double-digit percent of royalties.
  • Memo Therapeutics receives CHF 10.5 million from the federal COVID-19 drug grant program.
  • GlycoEra AG raises CHF 45 million (US$ 49 million) series A financing to develop novel biologics based on innovative glycoengineering platform.
  • Anjarium Biosciences Raises CHF 55.5 million ($61 million) Series A Financing to Develop Next-Generation Non-viral Gene Therapies.
  • Atlas Antibodies acquires evitria, a world leader in transient recombinant antibody expression in CHO cells.
  • Novartis signs a collaboration agreement and an option to acquire Cellerys. The start-up develops an innovative therapy against multiple sclerosis (MS).
  • Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuros’s license agreement with Checkmate Pharmaceuticals.
  • DiNAQOR Acquires EHT Technologies GmbH to Advance Engineered Heart Tissue R&D Capabilities.
  • FDA Approval of Aducanumab (ADUHELM), Neurimmune’s antibody treatment addressing the main pathology of Alzheimer’s disease.


  • Boehringer Ingelheim and CDR-Life enter into a collaboration and licensing agreement to research and develop antibody fragment-based therapeutics for geographic atrophy (GA). CDR-Life will be eligible to receive up to CHF 474.5 million in upfront and success-based milestone payments, as well as research funding and royalties on sales.
  • Collagen Matrix, Inc., a global leader in regenerative, collagen-based, xenograft-derived medical devices, acquires Sunstar’s Degradable Solutions division.
  • Memo raises CHF 14 million Series B financing to bring COVID-19 asset to the clinics.
  • Molecular Partners collaborates with Novartis to develop two DARPin® therapies designed for potential use against COVID-19. Molecular Partners will receive a cash payment of CHF 20 million, CHF 40 million in equity, a future milestone payment of CHF 150 million and 22% royalty on sales.
  • Kuros raises CHF 18.6 million in a capital increase.
  • Cutiss leads the ranking of the Top 100 Swiss Startup Award.
  • Virometix has successfully completed a CHF 7.5 million Series B equity financing round enabling
    the preclinical development of its vaccine candidates against SARS-CoV-2.
  • Molecular Partners successfully completes Private Placement of 5,528,089 Shares amounting to approximately CHF 80.2 million.
  • Cutiss secures more than CHF 20 million in a Series B financing round.
  • Proteomedix launches Proclarix® in Europe, a blood-based test for prostate cancer diagnosis.
  • Swissmedic appoval (FDA approval 2019) of Brolucizumab (Novartis: Beovu®) against wet AMD, developed at ESBATech in the Bio-Technopark.


  • SpineWelding receives U.S. Food and Drug Administration (FDA) 510(k) clearance for its Elaris Pedicle Screw System, which uses the patent protected BoneWelding process.
  • ImmunOs Therapeutics closes a Series A financing round of CHF 15 million led by Pfizer Ventures, Biomed Partners, Redalpine, Schroder Adveq, Wille Finance und Bernina Bioinvest.
  • Kuros announces final result of capital increase – total gross proceeds of CHF 12.5 million raised.
  • Cutiss wins Swiss Technology Award 2019 in the category startup.
  • Cantonal Pharmacy receives The Facility of the Year (FOYA) Award for the most innovative pharmaceutical infrastructure worldwide.
  • Appointment of Mario Jenni, Bio-Technopark, as Greater Zurich Honorary Ambassador.
  • NovaGo Therapeutics closes a Series A financing round of CHF 10 million led by Pureos Bioventures and the strategic partner Neurimmune.


  • Molecular Partners and Amgen announce strategic collaboration in immuno-oncology.
    Molecular Partners will receive an upfront payment of $50 million and is eligible to receive up to $497 million in development, regulatory and commercial milestone payments, as well as double-digit, tiered royalties up to the high teens.
  • Kuros announces final result of capital increase – total gross proceeds of CHF 16.1 million raised.
  • ProteoMediX raises CHF 5.2 million in financing round.
  • InSphero receives additional $10 million for organ-on-a-chip disease models. The latest funding round with additional financing, secured from internal and external investors, bringing its total funding to date to $35 million.
  • Neurimmune receives a one-time $50 million payment from its collaboration partner Biogen in exchange for a 5% reduction in the previously negotiated royalty rates on aducanumab.
  • The University Hospital Zurich (USZ), in cooperation with Roche Pharma (Schweiz) AG and Foundation Medicine Inc, Cambridge USA (FMI), offers a tumor test in the field of personalized cancer medicine. A specialized laboratory was set up in the Bio-Technopark to make the tumor test available to all cancer patients in Switzerland.